Evaluation and Management of Cardiovascular Risk Factors in Inflammatory and Acquired Dysimmune Diseases (CARMIN)
Study Details
Study Description
Brief Summary
The hypothesis is that chronic inflammatory dysimmune state promotes the development of cardiovascular complications. The biological assumption is based on the fact that chronic inflammation promotes lesions of the vessel wall (endothelial alterations, calcification, atherosclerosis). The clinical aim is to allow to identify high-risk patients and to act in prevention.
The project CARMIN involves the assessment of cardiovascular risk factors, their management, and their influence on cardiovascular prognosis in patients with autoimmune diseases and immunodeficiencies acquired. It is based on the creation and monitoring of a cohort of patients with different types of dysimmune disorders: systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma, systemic vasculitis ANCA, kidney transplants, and hematopoietic stem cells transplants.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Systemic lupus erythematosus Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years). |
Other: Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
|
| Rheumatoid arthritis Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years). |
Other: Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
|
| Psoriasis Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years). |
Other: Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
|
| Scleroderma Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years). |
Other: Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
|
| Hematopoietic stem cells transplants Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years). |
Other: Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
|
| Kidney transplants Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years). |
Other: Data collection
Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
|
Outcome Measures
Primary Outcome Measures
- The occurrence of any cardiovascular event (will be recorded from the patient files and/or phone calls to patient") [2 years]
The cardiovascular events : cardiovascular death, myocardial infarction, stroke, peripheral arterial disease, ischemic manifestations in other territories, heart failure, arrhythmia, deep vein thrombosis or pulmonary embolism.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients followed in the various services of medical specialties pole of the Edouard Herriot hospital
-
The diagnosis of the pathology selected for this study based on a clear clinical and biological evaluation supported by criteria specific to each pathology and compatible with international standards.
-
Date of diagnosis should not be less than 5 years (+/- 1 year), except for scleroderma patients where it has been extended to 10 years.
-
For kidney transplant patients the investigators take into account only patients with a maximum of 2 years of dialysis before graft.
Exclusion Criteria:
-
Diabetic patients
-
HIV seropositive
-
Patients with multiple pathologies
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Hospices Civils de Lyon
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- D50841